Streetbeat News

Products Services

GM

General Motors shares are trading lower after the company reported Q2 financial results and announced delays in its 2024 Buick EV and EV pickup plant opening to 2026.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 2:50 pm

CLRB

Cellectar Biosciences Inc. (NASDAQ:CLRB) stock is trading lower despite meeting the primary endpoint in its CLOVER WaM pivotal study for relapsed/refractory Waldenstrom’s macroglobulinemia. The study showed an overall response rate of 80% and a major response rate of 56.4%, exceeding the primary endpoint of 20% MRR. The company plans to file an FDA marketing application in Q4 2024.

Portfolio Pulse from Vandana Singh

July 23, 2024 | 2:49 pm

LLY

NVO

Novo Nordisk's weight-loss drug Wegovy has received approval in the UK for reducing the risk of heart disease. This approval could significantly boost the drug's market potential and Novo Nordisk's revenue.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 2:41 pm

MAIA

REGN

MAIA Biotechnology announced promising long-term benefits from its Phase 2 THIO-101 trial for advanced non-small-cell lung cancer patients. The trial, which combines MAIA's THIO with Regeneron's cemiplimab, shows high efficacy and low toxicity. Despite positive results, MAIA's stock is down 14.25%.

Portfolio Pulse from Vandana Singh

July 23, 2024 | 2:38 pm

LOGI

Logitech's CEO is optimistic about the company's sustainable growth and B2B market recovery. The CFO search is progressing well, with news expected soon. There will be no significant change in direction after the chair's departure. AI-enabled products are expected to enhance device appeal and pricing.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 2:36 pm

PM

Philip Morris International Inc. (NYSE:PM) reported better-than-expected Q2 FY24 earnings, raised its adjusted EPS outlook for 2024, and saw a 2.87% increase in share price. The company reported a 5.6% year-on-year revenue growth to $9.468 billion, with smoke-free products accounting for 38.1% of total net revenues. Adjusted EPS of $1.59 beat the consensus estimate of $1.57. The company also raised its FY24 adjusted EPS outlook to $6.33 – $6.45.

Portfolio Pulse from Shivani Kumaresan

July 23, 2024 | 2:26 pm

EYPT

Eyepoint Pharmaceuticals has been granted U.S. Patent #12043664 for methods to treat Vascular Leak Syndrome and cancer. This patent could potentially enhance their product portfolio and market position.

Portfolio Pulse from charles@benzinga.com

July 23, 2024 | 2:14 pm

BTCUSD

Crypto trader Scient has provided a detailed analysis of Bitcoin's key levels and triggers for buying and selling. The analysis includes specific 'Sell Zones,' 'Buy Zones,' and support/resistance levels, offering a roadmap for both current holders and potential investors. Scient suggests that consolidation above the mid-range support/resistance level could lead to a squeeze towards all-time high levels, while falling below certain buy zones could present buying opportunities.

Portfolio Pulse from Khyathi Dalal

July 23, 2024 | 2:14 pm

INM

Inmed Pharmaceuticals has been granted U.S. Patent #12042479 for the use of topical formulations of cannabinoids in the treatment of Epidermolysis Bullosa and related connective tissue disorders.

Portfolio Pulse from charles@benzinga.com

July 23, 2024 | 2:11 pm

CVS

CVS Caremark has announced a commitment to enhance transparency, reduce prescription drug costs, strengthen pharmacy relations, and deliver top clinical care. The company aims to support American businesses, unions, and health plans through these initiatives.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 2:10 pm